Copyright
©The Author(s) 2021.
World J Diabetes. Jun 15, 2021; 12(6): 706-729
Published online Jun 15, 2021. doi: 10.4239/wjd.v12.i6.706
Published online Jun 15, 2021. doi: 10.4239/wjd.v12.i6.706
Table 3 Effects of osteoporosis medications in patients with type 2 diabetes mellitus
| Medication | Effect on glucose metabolism | BMD | Risk of fracture |
| Alendronate | Reduction in the risk of diabetes | Increase | NA/unchanged |
| Risedronate | Reduction in the risk of diabetes | Increase | NA |
| Etidronate | NA | NA | Unchanged |
| Denosumab | No effect on blood glucoselevels | Increase | Decrease |
| Raloxifene | Improves insulin sensitivity | NA | Decrease/unchanged |
| Teriparatide | No effect blood glucose levels | Increase | Unchanged |
- Citation: Palui R, Pramanik S, Mondal S, Ray S. Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus. World J Diabetes 2021; 12(6): 706-729
- URL: https://www.wjgnet.com/1948-9358/full/v12/i6/706.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i6.706